These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 33593794)

  • 1. Enhancing the Generation of Eomes
    Emerson DA; Rolig AS; Redmond WL
    Cancer Immunol Res; 2021 Apr; 9(4):430-440. PubMed ID: 33593794
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined targeting of costimulatory (OX40) and coinhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust antitumor immunity.
    Redmond WL; Linch SN; Kasiewicz MJ
    Cancer Immunol Res; 2014 Feb; 2(2):142-53. PubMed ID: 24778278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T-cell anergy and promotes survival in tumor-bearing mice.
    Linch SN; Kasiewicz MJ; McNamara MJ; Hilgart-Martiszus IF; Farhad M; Redmond WL
    Proc Natl Acad Sci U S A; 2016 Jan; 113(3):E319-27. PubMed ID: 26729864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blockade of CTLA-4 and PD-1 Enhances Adoptive T-cell Therapy Efficacy in an ICOS-Mediated Manner.
    Shi LZ; Goswami S; Fu T; Guan B; Chen J; Xiong L; Zhang J; Ng Tang D; Zhang X; Vence L; Blando J; Allison JP; Collazo R; Gao J; Sharma P
    Cancer Immunol Res; 2019 Nov; 7(11):1803-1812. PubMed ID: 31466995
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eomesodermin(lo) CTLA4(hi) Alloreactive CD8+ Memory T Cells Are Associated With Prolonged Renal Transplant Survival Induced by Regulatory Dendritic Cell Infusion in CTLA4 Immunoglobulin-Treated Nonhuman Primates.
    Ezzelarab MB; Lu L; Guo H; Zahorchak AF; Shufesky WF; Cooper DK; Morelli AE; Thomson AW
    Transplantation; 2016 Jan; 100(1):91-102. PubMed ID: 26680373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8
    Peng W; Williams LJ; Xu C; Melendez B; McKenzie JA; Chen Y; Jackson HL; Voo KS; Mbofung RM; Leahey SE; Wang J; Lizee G; Tawbi HA; Davies MA; Hoos A; Smothers J; Srinivasan R; Paul EM; Yanamandra N; Hwu P
    Clin Cancer Res; 2019 Nov; 25(21):6406-6416. PubMed ID: 31371342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
    Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
    Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
    [No Abstract]   [Full Text] [Related]  

  • 8. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells.
    Jahan N; Talat H; Curry WT
    Neuro Oncol; 2018 Jan; 20(1):44-54. PubMed ID: 29016879
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
    Kvarnhammar AM; Veitonmäki N; Hägerbrand K; Dahlman A; Smith KE; Fritzell S; von Schantz L; Thagesson M; Werchau D; Smedenfors K; Johansson M; Rosén A; Åberg I; Winnerstam M; Nyblom E; Barchan K; Furebring C; Norlén P; Ellmark P
    J Immunother Cancer; 2019 Apr; 7(1):103. PubMed ID: 30975201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of eomesodermin and T-bet expression by allostimulated CD8
    Perez-Gutierrez A; Metes DM; Lu L; Hariharan S; Thomson AW; Ezzelarab MB
    Clin Exp Immunol; 2018 Nov; 194(2):259-272. PubMed ID: 30246373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy.
    Furusawa A; Reiser J; Sadashivaiah K; Simpson H; Banerjee A
    J Immunother; 2018; 41(2):53-63. PubMed ID: 29271784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual anti-OX40/IL-2 therapy augments tumor immunotherapy via IL-2R-mediated regulation of OX40 expression.
    Redmond WL; Triplett T; Floyd K; Weinberg AD
    PLoS One; 2012; 7(4):e34467. PubMed ID: 22496812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo.
    Redmond WL; Gough MJ; Weinberg AD
    Eur J Immunol; 2009 Aug; 39(8):2184-94. PubMed ID: 19672905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.
    Nawaf MG; Ulvmar MH; Withers DR; McConnell FM; Gaspal FM; Webb GJ; Jones ND; Yagita H; Allison JP; Lane PJL
    J Immunol; 2017 Aug; 199(3):974-981. PubMed ID: 28646041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinatorial immunotherapeutic approaches to restore the function of anergic tumor-reactive cytotoxic CD8
    Redmond WL; Linch SN
    Hum Vaccin Immunother; 2016 Oct; 12(10):2519-2522. PubMed ID: 27459422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist.
    Redmond WL; Gough MJ; Charbonneau B; Ratliff TL; Weinberg AD
    J Immunol; 2007 Dec; 179(11):7244-53. PubMed ID: 18025166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence.
    Buchan S; Manzo T; Flutter B; Rogel A; Edwards N; Zhang L; Sivakumaran S; Ghorashian S; Carpenter B; Bennett C; Freeman GJ; Sykes M; Croft M; Al-Shamkhani A; Chakraverty R
    J Immunol; 2015 Jan; 194(1):125-133. PubMed ID: 25404365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.
    Mittal P; Abblett R; Ryan JM; Hagymasi AT; Agyekum-Yamoah A; Svedova J; Reiner SL; St Rose MC; Hanley MP; Vella AT; Adler AJ
    J Immunol; 2018 Feb; 200(4):1513-1526. PubMed ID: 29305435
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eomes-Dependent Loss of the Co-activating Receptor CD226 Restrains CD8
    Weulersse M; Asrir A; Pichler AC; Lemaitre L; Braun M; Carrié N; Joubert MV; Le Moine M; Do Souto L; Gaud G; Das I; Brauns E; Scarlata CM; Morandi E; Sundarrajan A; Cuisinier M; Buisson L; Maheo S; Kassem S; Agesta A; Pérès M; Verhoeyen E; Martinez A; Mazieres J; Dupré L; Gossye T; Pancaldi V; Guillerey C; Ayyoub M; Dejean AS; Saoudi A; Goriely S; Avet-Loiseau H; Bald T; Smyth MJ; Martinet L
    Immunity; 2020 Oct; 53(4):824-839.e10. PubMed ID: 33053331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.